D.R.I.V.E: Developing Research Initiatives through Versatile Oncology Exploration

总体：摘要 自2018年获得NCI认定以来，俄克拉荷马州大学的斯蒂芬森癌症中心（SCC） 作为一个组织，它不断成长和成熟。SCC在俄克拉荷马州消除癌症的愿景， 超越是通过其使命，以提供以病人为中心，研究驱动，多学科的癌症 关心所有俄克拉荷马人。作为俄克拉荷马州唯一一家NCI指定的癌症中心，SCC为全州范围内的 这是一个集水区，在健康的社会决定因素和 癌症发病率和死亡率，特别是该州的美洲印第安人（AI），黑人/非洲裔美国人， 农村人口。SCC有能力在其集水区和全国范围内产生影响，因为 具有战略针对性的招聘和投资，利用了关键的差异化因素：1）SCC 继续投资于与AI部落合作伙伴建立和维持健康和研究伙伴关系 整个俄克拉荷马州，目前有22个NIH资助的项目，解决AI癌症的差异; 2）SCC 继续成为NCI/NCTN的全国领导者，并建立了全州范围的附属网站网络， 确保在其整个集水区获得NCI申办的临床试验; 3）SCC已经发展强大 以团队为基础的研究，在其所有项目中，在妇科、结肠和胰腺方面处于国家领导地位。 癌症，癌症预防，癌症治疗，老年肿瘤学和烟草控制;以及4）SCC是 利用其在移动的保健技术方面的国家领导地位， 弱势群体。 多个NCI CCSG指标强调SCC在报告期内的增长和成熟 （2017-21）。SCC成员从83个增加到120个（45%），其中31个新成员来自外部 被招募来为项目增加专业知识。年度，同行评审的研究资金（DC）增长了61%（1428万美元） 2297万美元），年度研究经费总额增长了42%（3013万美元至4309万美元）。五年来， 自上次报告期（945 - 1，454）以来，科学出版物增加了54%，其中16%的科学出版物 影响因子≥10（高于7%）。团队科学一直强调导致139合作赠款 (36与前一报告期相比，计划间出版率为17%（高于4%）。 在过去五年中，每年活跃的干预性IIT数量从20个增加到40个， 干预性IIT的应计费用从661（2017年）增加到927（2021年）-增加了40%。这种程度的 由于通过CCSG提供的基础设施， 将SCC定位为成功更新为NCI指定的癌症中心。

OVERALL: ABSTRACT Since achieving NCI designation in 2018, the Stephenson Cancer Center (SCC) at the University of Oklahoma has continued to grow and mature as an organization. The SCC’s vision to eliminate cancer in Oklahoma and beyond is advanced through its mission to provide patient-centered, research-driven, multidisciplinary cancer care to all Oklahomans. As Oklahoma’s only NCI-designated cancer center, the SCC serves a statewide catchment area that presents unique challenges with social determinants of health and high disparities in cancer incidence and mortality, especially for the state’s American Indian (AI), Black/African American, and rural populations. The SCC has the ability to be impactful in its catchment area and nationally due to strategically targeted recruitments and investments that have leveraged key differentiating factors: 1) the SCC continues to invest in creating and sustaining health and research partnerships with AI tribal partners throughout Oklahoma and currently has 22 NIH funded projects addressing AI cancer disparities; 2) the SCC continues to be a national leader in the NCI/NCTN and has established a statewide network of affiliate sites to ensure access to NCI-sponsored clinical trials throughout its catchment area; 3) the SCC has developed strong team-based research across all of its programs with national leadership in gynecologic, colon, and pancreatic cancers, cancer prevention, cancer therapeutics, gero-oncology, and tobacco control; and 4) the SCC is building upon its national leadership in mobile health technologies to address the burden on cancer in rural and vulnerable populations. Multiple NCI CCSG metrics emphasize the growth and maturation of the SCC during the reporting period (2017-21). SCC membership increased from 83 to 120 (45%), with 31 of these new members being externally recruited to add expertise to programs. Annual, peer-reviewed research funding (DC) grew 61% ($14.28M  $22.97M) and total annual research funding grew 42% ($30.13M  $43.09M). The overall five-year number of scientific publications has increased by 54% since the last reporting period (945  1,454), with 16% having an impact factor ≥10 (up from 7%). Team science has been emphasized resulting in 139 collaborative grants (36% increase) and a 17% inter-programmatic publication rate (up from 4%) over the prior reporting period. The number of annual active interventional IITs has doubled from 20 to 40 over the past five years, with annual accruals to interventional IITs increasing from 661 (2017) to 927 (2021) – a 40% increase. This degree of impactful growth has been possible due to the infrastructure made available through the CCSG and has positioned the SCC for a successful renewal as a NCI-designated cancer center.